Comparison of Serum Hepatitis B Virus RNA Levels and Quasispecies Evolution Patterns between Entecavir and Pegylated-Interferon Mono-treatment in Chronic Hepatitis B Patients
Open Access
- 24 August 2020
- journal article
- research article
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 58 (9)
- https://doi.org/10.1128/jcm.00075-20
Abstract
Hepatitis B virus (HBV) RNA may independently predict virological and serological response. This study aimed to compare dynamic changes in serum HBV RNA levels and HBV quasispecies evolution patterns between entecavir and pegylated-interferon mono-treatment in chronic hepatitis B patients and to determine the clinical significance during treatment. TaqMan real-time PCR was used for quantitative analysis. HBV RNA levels were retrospectively determined in serial serum samples from 178 chronic hepatitis B patients who received either entecavir or pegylated-interferon treatment. Both serum HBV DNA and RNA quasispecies were analyzed via next-generation sequencing. Receiver operating characteristics (ROC) analysis was performed to evaluate the prediction value of individual biomarkers for hepatitis B e antigen (HBeAg) seroconversion. Patients who received pegylated-interferon treatment showed stronger declines in HBV RNA levels than did those who received entecavir treatment. Serum HBV RNA levels were lower in patients with subsequent HBeAg seroconversion. At baseline, the level of HBV RNA was better than other indicators in predicting HBeAg seroconversion. Moreover, the predictive value of serum HBV RNA levels was better in the entecavir group. Baseline HBV RNA exhibited a significantly higher genetic diversity than HBV DNA and had a significant decline after 4 weeks of entecavir treatment. Higher baseline genetic diversity may result in a better outcome in pegylated-interferon-treated patients. Serum HBV RNA levels showed different decline kinetics, and HBV RNA quasispecies showed different evolution patterns in entecavir and pegylated-interferon mono-treatment. Taken together, serum HBV RNA may serve as a promising biomarker of HBeAg seroconversion in patients during antiviral treatment.Keywords
Funding Information
- National Science and Technology Major Project (2017ZX10202202)
- Shanghai International Collaboration Project (16410711900)
- National Science and Technology Major Project (2018ZX10302204-001-003)
- National Natural Science Foundation of China (81672069)
- Shanghai Shen Kang Hospital Development Center (SHDC12016101)
This publication has 35 references indexed in Scilit:
- Serum hepatitis B virus RNA levels as an early predictor of hepatitis B envelope antigen seroconversion during treatment with polymerase inhibitorsJournal of Hepatology, 2014
- On-Treatment Low Serum HBV RNA Level Predicts Initial Virological Response in Chronic Hepatitis B Patients Receiving Nucleoside Analogue TherapyAntiviral Therapy, 2014
- Comparison of Next-Generation Sequencing and Clone-Based Sequencing in Analysis of Hepatitis B Virus Reverse Transcriptase Quasispecies HeterogeneityJournal of Clinical Microbiology, 2013
- Long-term hepatitis B surface antigen (HBsAg) kinetics during nucleoside/nucleotide analogue therapy: Finite treatment duration unlikelyJournal of Hepatology, 2012
- Shorter durations and lower doses of peginterferon alfa-2a are associated with inferior hepatitis B e antigen seroconversion rates in hepatitis B virus genotypes B or CJournal of Hepatology, 2011
- ShoRAH: estimating the genetic diversity of a mixed sample from next-generation sequencing dataBMC Bioinformatics, 2011
- Evolutionary patterns of hepatitis B virus quasispecies under different selective pressures: correlation with antiviral efficacyGut, 2011
- Error correction of next-generation sequencing data and reliable estimation of HIV quasispeciesNucleic Acids Research, 2010
- Differential effects of interferon and lamivudine on serum HBV RNA inhibition in patients with chronic hepatitis BAntiviral Therapy, 2010
- Expression of the terminal protein of hepatitis B virus is associated with failure to respond to interferon therapyJournal of Hepatology, 1993